Inhibrx, Inc. (INBX) is a San Diego, California-based biotechnology company specializing in the development of novel therapies that help manage or treat severe ailments. Founded in 2010, the company utilizes its advanced protein engineering technologies to create innovative therapeutic candidates that offer potential solutions for patients with high unmet clinical needs. Inhibrx's mission is to enhance the quality of life and longevity of people battling serious diseases, focusing particularly on conditions like cancer, pulmonary diseases, and rare ailments.
INBX has introduced an array of experimental therapies into active clinical trials. Its extensive product portfolio includes INBRX-109, designed for treating various types of solid tumor malignancies; INBRX-105, intended for refractory solid tumors; INBRX-106, made for hepatic immune stimulation, and INBRX-101, developed for Alpha-1 Antitrypsin Deficiency (AATD).
The company's diverse therapeutic pipeline distinguishes it from many biotech startups. Its versatile approach to drug development employing its proprietary SDAB and tetravalent single molecule platform technologies has enabled it to create highly potent biologics. They’ve created over 2,000 therapeutic candidates within their pipeline using this technology, showcasing the productivity and capabilities of their innovative platform.
Inhibrx's track record of established partnerships with prominent companies like Bristol-Myers Squibb and Celgene showcases its notable presence in the biotechnology industry. These collaborations provide non-dilutive funding to support the company's internal development objectives and the potential for considerable future milestones and royalties.
In August 2020, Inhibrx went public on the NASDAQ exchange under the ticker symbol INBX. The initial public offering of Inhibrx's stock significantly increased the company's ability to raise capital for continued product development and research efforts.
Cognizant of the undeniable power of efficient and effective drug discovery, Inhibrx advances with an unwavering commitment to innovation. Its persistent pursuit of transformative therapies and ground-breaking scientific breakthroughs enables it to render a significant impact on patients' lives globally.
While Inhibrx's journey is lined with challenges typical in the drug development industry, it has shown an outstanding ability to leverage scientific innovation to produce promising drug candidates. The company's impact and potential in the biotech field are expected to grow as it continues to advance its robust pipeline of unique biologic therapeutic candidates.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
_07_03_2026_03_50_21_133108.jpg)
Kimberly Manhard, a Director at Inhibrx Biosciences, Inc. (NASDAQ:INBX), submitted an amended Form 4/A to the SEC, correcting the number of stock options granted to her due to an administrative error. The filing confirms she received options for 10,000 shares of common stock at an exercise price of $95.22, granted on June 3, 2026. These options will vest fully on June 3, 2027, provided she continues her service, and will expire on June 3, 2036.
Inhibrx announced positive interim results from its Phase 2 HexAgon study for INBRX-106 in Head and Neck Squamous Cell Carcinoma (HNSCC), showing a confirmed objective response rate of 48.3% and a median progression-free survival of 9.6 months when combined with pembrolizumab. The treatment, particularly effective in HPV+ patients, nearly doubled the response rate and significantly improved progression-free survival compared to pembrolizumab alone. Inhibrx plans to expand the study in HPV+ patients for a potential accelerated approval pathway and explore INBRX-106's use in other immunogenic tumors and cancer vaccine combinations.
Inhibrx Biosciences (INBX) reported a wider net loss in Q2 2026, yet its shares have seen significant gains year-to-date and over the last year. The company's negative price-to-book ratio of -27.5x indicates that its valuation is driven by future drug development potential rather than current net assets, due to liabilities exceeding assets. Investors are advised to consider both the potential rewards and risks, including clinical trial setbacks or equity dilution.
Western Standard LLC has acquired a new position in Inhibrx Biosciences, Inc. (NASDAQ:INBX), purchasing 47,000 shares valued at approximately $4.45 million, making it the fund's 19th largest holding. Despite this institutional interest, analyst sentiment is mixed, with a consensus "Hold" rating and an average price target of $150. Inhibrx Biosciences recently reported a quarterly loss of $2.34 per share, missing consensus estimates.
Wall Street Zen has downgraded Inhibrx Biosciences (NASDAQ:INBX) to a "strong sell" rating, despite a mixed outlook from other analysts, with the overall consensus remaining "Hold" and an average price target of $150. The company's shares opened at $88.37, significantly below its 12-month high, and it recently reported a quarterly loss that missed analyst expectations. Institutional investors hold a substantial stake in the company, with firms like Morgan Stanley and BlackRock among its major shareholders.
Inhibrx Biosciences reported widening net losses in Q2 2026, alongside key clinical milestones including FDA acceptance of ozekibart's biologics license application with a PDUFA goal date of April 14, 2027, and upcoming Phase 2 data for INBRX-106. While these regulatory and clinical advancements are significant, the company's financial results and reliance on capital emphasize the ongoing risk-reward balance for investors. The article suggests that despite these milestones, the stock price might be too optimistic, urging investors to conduct thorough research.
This article provides an in-depth analysis of Inhibrx Biosciences Inc (INBX), highlighting strong sentiment across all time horizons and an exceptional 100.9:1 risk-reward setup. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide trading decisions.